Baycol Apr 2026

By 2001, the evidence became impossible to ignore. Internal documents later suggested that Bayer may have been aware of these risks as early as the drug's US approval in 1997. On , Bayer voluntarily withdrew Baycol from the global market following reports linking it to 31 deaths in the U.S. and dozens more worldwide. Study: Baycol risks greaterthan believed - NBC News

In the late 1990s, the pharmaceutical world was in a race to solve a growing global health crisis: high cholesterol. Bayer, the German pharmaceutical giant, introduced Baycol in 1997 as a powerful addition to the "statin" family—a class of drugs designed to block cholesterol production in the liver. baycol

The story of (cerivastatin) is a cautionary tale of a medical breakthrough that turned into a pharmaceutical crisis, ultimately leading to one of the most significant drug recalls in history. The Rise of a "Blockbuster" By 2001, the evidence became impossible to ignore